Dopamine agonists for restless legs syndrome.

Area of Science:

• Neurology
• Pharmacology
• Sleep Medicine

Background:

• Dopamine agonists are recommended as a first-line treatment for restless legs syndrome (RLS) according to clinical guidelines.
• Evaluating the efficacy and safety of these agents is crucial for patient care.

Purpose of the Study:

• To systematically evaluate the efficacy and safety of dopamine agonists in treating restless legs syndrome (RLS).

Main Methods:

• A comprehensive literature search was conducted across multiple databases (Cochrane, MEDLINE, EMBASE, PsycINFO, CINAHL) from 1985 to 2008.
• Included were double-blind randomized controlled trials (RCTs) of dopamine agonists versus placebo or active comparators in adult RLS patients.
• Outcomes assessed included the International RLS Severity Rating Scale (IRLS), sleep quality, quality of life, and safety parameters.

Main Results:

• Thirty-five placebo-controlled and three active-controlled RCTs involving 7365 patients were analyzed.
• Dopamine agonists significantly reduced IRLS scores and periodic limb movements in sleep compared to placebo.
• Improvements were noted in self-rated sleep quality and quality of life, but patients experienced more adverse events and higher dropout rates.

Conclusions:

• Meta-analyses confirm the superiority of dopamine agonists over placebo for RLS treatment in trials up to seven months.
• Specific agents like cabergoline and pramipexole demonstrated greater efficacy than levodopa in certain outcomes.
• Reliable assessment of augmentation, a severe side effect, remains a challenge.